Shares in Sartorius Stedim Biotech show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed. Investors should buy the stock at current prices near € 173 in order to target the € 193.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 50% by 2022.
The group's high margin levels account for strong profits.
The company is in a robust financial situation considering its net cash and margin position.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For several months, analysts have been revising their EPS estimates roughly upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 139.9 EUR
The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
The company's "enterprise value to sales" ratio is among the highest in the world.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.